Kaposi's sarcoma natural history: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
(19 intermediate revisions by 9 users not shown)
Line 1: Line 1:
{{CMG}}
__NOTOC__
{{CMG}}; {{AE}} {{Rim}} {{ADS}} {{Hudakarman}}
{{Kaposi's sarcoma}}
{{Kaposi's sarcoma}}


==Overview==
==Overview==
With the decrease in the death rate among AIDS patients receiving new treatments in the 1990s, the incidence and severity of epidemic KS also decreased. However, the number of patients living with AIDS is increasing substantially in the United States, and it is possible that the number of patients with AIDS-associated Kaposi's sarcoma will again rise as these patients live longer with HIV infection.
The [[prognosis]] of Kaposi's sarcoma (KS) depends on its [[histological]] type, whether the [[cancer]] has spread, and the general health status of the [[patient]]. When stratified by [[age]], the 5-year relative [[survival]] of [[patients]] with Kaposi sarcoma was 68.6% and 87.5% for patients <65 and ≥ 65 years of [[age]] respectively.


==Natural history==
==Natural History==
The disease is named after [[Moritz Kaposi]] (1837&ndash;1902), a Hungarian [[dermatologist]] who first described the symptoms in 1872. Research over the next century suggested that KS, like some other forms of cancer, might be caused by a virus or genetic factors, but no definite cause was found.
[[Kaposi's sarcoma-associated herpesvirus]] (KSHV) [[infection]] does not always lead to KS; it is still unclear what other factors may be required, such as preexisting [[immune system]] damage, or a specific interaction with [[HIV]] or other [[viruses]]. However, [[research]] in Africa has shown that even in the absence of [[HIV AIDS|HIV]]/[[AIDS]], KS is more common in men than women although KSHV infection is equal between both sexes. This suggests that [[sex hormone]]s may either protect from or predispose to KS in persons infected with the [[virus]].  Growth can range from very slow to explosively fast, and be associated with significant [[mortality]] and [[morbidity]].<ref name="SEER">Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.</ref>


With the rise of the AIDS epidemic, KS, as initially one of the most common AIDS symptoms, was researched more intensively in hopes that it might reveal the cause of AIDS.
==Prognosis==
 
The [[prognosis]] of Kaposi's sarcoma depends on the following:
In 1994, [[Yuan Chang]],  [[Patrick S. Moore]], and Ethel Cesarman at Columbia University in New York isolated genetic pieces of a virus from a KS lesion. They used [[representational difference analysis]] (a method to subtract out all of the human DNA from a sample) to isolate the viral genes. They then used these small DNA fragments as starting points to sequence the rest of the viral genome in 1996. This, the eighth human herpesvirus (HHV-8)&#151;now known as Kaposi's sarcoma-associated herpesvirus (KSHV)&#151;has since been found in all KS lesions tested, and is considered the cause of the disease. KSHV is a unique human tumor virus that has incorporated cellular genes that cause tumors into its genome ("molecular piracy"); the stolen cellular genes may help the virus escape from the immune system, but in doing so it also causes cells to proliferate.  It is related to [[Epstein-Barr virus]], a very common herpesvirus that can also cause human cancers.


KSHV infection does not always lead to KS; it is still unclear what other factors may be required, such as pre-existing immune system damage, or a specific interaction with HIV or other viruses. However, research in Africa has shown that even in the absence of HIV/AIDS, KS is more common in men than women although KSHV infection is equal between both sexes.  This suggests that [[sex hormone]]s may either protect from or predispose to KS in persons infected with the virus.
* The type of Kaposi sarcoma
* Whether the [[cancer]] has spread
* Whether the [[cancer]] has just been [[Diagnosis|diagnosed]] or has recurred
* The patient's general [[health]], especially the [[immune system]]


==Complications==
===5-Year Survival===
* Between 2004 and 2010, the 5-year relative [[Survival rate|survival]] of [[patients]] with Kaposi sarcoma was 72%.<ref name="SEER">Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.</ref>


==Prognosis==
* When stratified by [[age]], the 5-year relative [[Survival rates|survival]] of [[patients]] with Kaposi sarcoma was 68.6% and 87.5% for patients <65 and ≥ 65 years of [[age]] respectively.<ref name="SEER">Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.</ref>


==References==
==References==
{{Reflist|2}}
{{Reflist|2}}
[[Category:Disease]]
[[Category:HIV/AIDS]]
[[Category:Types of cancer]]
[[Category:Dermatology]]
[[Category:Pulmonology]]
[[Category:Gastroenterology]]
{{WH}}
{{WS}}
[[Category:Up-To-Date]]
[[Category:Oncology]]
[[Category:Medicine]]
[[Category:Vascular medicine]]
[[Category:Surgery]]

Latest revision as of 14:00, 10 October 2019

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rim Halaby, M.D. [2] Amandeep Singh M.D.[3] Huda A. Karman, M.D.

Kaposi's sarcoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Kaposi's sarcoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

Echocardiograph and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Kaposi's sarcoma natural history On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Kaposi's sarcoma natural history

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Kaposi's sarcoma natural history

CDC on Kaposi's sarcoma natural history

Kaposi's sarcoma natural history in the news

Blogs on Kaposi's sarcoma natural history

Directions to Hospitals Treating Kaposi's sarcoma

Risk calculators and risk factors for Kaposi's sarcoma natural history

Overview

The prognosis of Kaposi's sarcoma (KS) depends on its histological type, whether the cancer has spread, and the general health status of the patient. When stratified by age, the 5-year relative survival of patients with Kaposi sarcoma was 68.6% and 87.5% for patients <65 and ≥ 65 years of age respectively.

Natural History

Kaposi's sarcoma-associated herpesvirus (KSHV) infection does not always lead to KS; it is still unclear what other factors may be required, such as preexisting immune system damage, or a specific interaction with HIV or other viruses. However, research in Africa has shown that even in the absence of HIV/AIDS, KS is more common in men than women although KSHV infection is equal between both sexes. This suggests that sex hormones may either protect from or predispose to KS in persons infected with the virus. Growth can range from very slow to explosively fast, and be associated with significant mortality and morbidity.[1]

Prognosis

The prognosis of Kaposi's sarcoma depends on the following:

5-Year Survival

  • Between 2004 and 2010, the 5-year relative survival of patients with Kaposi sarcoma was 72%.[1]
  • When stratified by age, the 5-year relative survival of patients with Kaposi sarcoma was 68.6% and 87.5% for patients <65 and ≥ 65 years of age respectively.[1]

References

  1. 1.0 1.1 1.2 Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.


Template:WH Template:WS